Navigation Links
Orexigen Announces June 10, 2014 PDUFA Action Date for Contrave
Date:1/7/2014

SAN DIEGO, Jan. 7, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), today announced that the United States Food and Drug Administration (FDA) considers the recent resubmission of the Contrave® (naltrexone sustained release (SR)/bupropion SR) New Drug Application to be a complete response to the FDA's prior January 31, 2011 action letter. For the resubmission, the FDA has assigned a Prescription Drug User Fee Act goal date of June 10, 2014. If approved, the Company expects commercial launch of Contrave by North American partner Takeda Pharmaceuticals in the second half of 2014.

"We will continue to work closely with the FDA during the review of the Contrave NDA resubmission, and, if approved, we and Takeda look forward to making Contrave available to patients soon thereafter," said Michael Narachi, CEO of Orexigen.

Orexigen resubmitted the Contrave NDA in December 2013 following the earlier announcement of the successful interim analysis of the Light Study, the Contrave cardiovascular outcomes trial.

About the Light Study
The Contrave Light Study is a double-blind, placebo-controlled cardiovascular outcomes trial that randomized approximately 8,900 patients. The primary objective of the Light Study, which Orexigen is conducting under a Special Protocol Assessment with the FDA at approximately 260 clinical sites in the United States, is to rule out excess cardiovascular risk in overweight and obese patients receiving Contrave. In November 2013 Orexigen announced successful results of the interim analysis of the Light Study, stating that it met the prespecified criteria to exclude a hazard ratio of 2.0, using the upper bound of the 95% confidence interval, for excess risk of major adverse cardiovascular events (MACE) in patients receiving Contrave as
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... protection, repair and regeneration, today announced that J.J. ... to present a corporate overview at two upcoming investor ... the SeeThruEquity 4 th Annual Microcap Conference on ... City at 11:00 am EDT.  A webcast ...
(Date:5/22/2015)... NEW YORK and KING OF PRUSSIA, ... Hemophilia Foundation (NHF) has awarded CSL Behring ... longstanding and unwavering commitment to advancing science and improving the ... by Paul Perreault , CEO and Managing Director, CSL ... New York City on May 21. ...
(Date:5/22/2015)... 22, 2015  The Mesothelioma Victims Center is ... mesothelioma get the best possible compensation, and they are ... this rare cancer caused by exposure to asbestos ... related to treatment options such as a recent ... Mesothelioma Victims Center anytime at 866-714-6466. http://MesotheliomaVictimsCenter.Com ...
Breaking Medicine Technology:RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5
... WOBURN, Mass. , Feb. 16 Energetiq Technology, ... advanced technology applications, will introduce its Laser-Driven Light Source (LDLS™) ... world at the Biophysical Society 54th Annual Meeting in ... light sources are well suited to challenging applications such as ...
... , , BOCA ... today that its NutraRx brand of natural dietary supplements ... receive the Emerson EQP Seal in recognition of the high quality ... rigorous evaluation by Emerson Ecologics of our NutraRx brand of products ...
Cached Medicine Technology:Energetiq Introduces Laser-Driven Light Sources for Biophysical Applications 2Native Remedies' NutraRx Brand of Natural Products for Medical Practitioners Among First to Earn Prestigious 'Emerson EQP Seal' 2Native Remedies' NutraRx Brand of Natural Products for Medical Practitioners Among First to Earn Prestigious 'Emerson EQP Seal' 3
(Date:5/24/2015)... (PRWEB) May 24, 2015 ... System CEO - The students ... honored at the fourth annual A ... 15 at Geneva National in Lake ... ,     -Badger High School,         Jonathan Alfonso, ...
(Date:5/23/2015)... CA (PRWEB) May 23, 2015 With ... small businesses, are finding it increasingly difficult to provide ... which fail to provide adequate insurance for employees stand ... businesses been such an integral part of a business’s ... affordable healthcare for businesses, Online USA Doctors has created ...
(Date:5/23/2015)... Javon Bea Mercy Health System CEO ... Center, 557 N. Washington St., Janesville, will host an ... pm. , The 8-week clinic is lead by Brent ... who will offer training that encompasses a warm-up, training ... show selection and weekly training plans. , The program ...
(Date:5/22/2015)... May 22, 2015 The American College ... events in June. They will hold a webinar on ... a two-day class on Classical Chinese Medicine. , Webinar ... Dr. Steve Given, the Dean of Clinical Education, will ... new First Professional Doctorate program. ACTCM is currently developing ...
(Date:5/22/2015)... 2015 Omar Ahmad Barrada, a junior ... in the 2015 Congress of Future Medical Leaders in ... gathering of “America’s highest achieving high school students.” , ... set new goals and learn better study habits,” said ... during which we can ask the surgeons questions.” , ...
Breaking Medicine News(10 mins):Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:ACTCM Announces Upcoming June Events 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2
... (PBCC) will hold a press conference on Monday,March 24 ... Flyers-76ers,Surgery Theatre on the main floor of One Ravdin ... Tax Check-Off for Breast and,Cervical Cancer Research campaign and ... receive research grants., Scheduled to speak at the ...
... Ill., March 19 Sagent Pharmaceuticals,Inc., a ... has launched ciprofloxacin injection, USP, 5% dextrose ... for intravenous (I.V.),administration used to treat bacterial ... in 200mg and 400mg premix bags.,According to ...
... March 19 GlaxoSmithKline (NYSE: GSK ),today ... totaled,$564 million, equivalent to almost 4% of pre-tax ... around 1%). Donations of albendazole treatments,for the company,s ... elephantiasis) were valued at $29 million, bringing the,total ...
... groups of 120 members of the U.S. House ... the Centers for Medicare and Medicaid,Services (CMS) raising ... bidding program on small durable medical equipment (DME),providers. ... how the bidding program,will impact thousands of small ...
... also more prone, new study finds , , WEDNESDAY, March 19 ... on a number of factors and is more likely to ... A team at the University of Turin analyzed the medical ... between 1994 and 2006. Of those patients, 540 (77 percent) ...
... 19, 2008) -- Being too brainy can be a ... social hierarchy favors other traits. "Braininess" also causes problems ... proteins normally produced in neurons, for example, it can ... laboratory at Harvard Medical School (HMS) have identified some ...
Cached Medicine News:Health News:The Pennsylvania Breast Cancer Coalition Announces Event at the University of Pennsylvania Hospital to Celebrate the 2008 Income Tax Check-Off Campaign 2Health News:Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag 2Health News:GSK Charitable Support Valued at $564 Million in 2007 2Health News:GSK Charitable Support Valued at $564 Million in 2007 3Health News:Medicare Bidding Program for Durable Medical Equipment May Harm Small Businesses and Decrease Patient Access to Care, Say 137 Members of Congress 2Health News:Medicare Bidding Program for Durable Medical Equipment May Harm Small Businesses and Decrease Patient Access to Care, Say 137 Members of Congress 3Health News:Women at Higher Risk of Abnormal Burn Scars 2Health News:Neuronal regulators offer potential targets for cancer 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: